Galectin-9 as a new biomarker of acute-on-chronic liver failure.
ACLF
Clinical diagnosis
Gal-9
Hepatology
Prognosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
05
06
2024
accepted:
17
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
Galectin-9 (Gal-9) expression in patients with acute-on-chronic liver failure and its correlation with prognosis remain unclear. This study investigated the relationship between liver failure prognosis and Gal-9 expression analysis in patients with acute-on-chronic liver failure. Patients with acute-on-chronic liver failure attributable to hepatitis B and those with chronic hepatitis B were included in this single-center prospective cohort study. The Gal-9 levels in the acute-on-chronic liver failure group were significantly higher than those in the chronic hepatitis B group, and there was an upregulation of Gal-9 and T-cell immunoglobulin domain and mucin domain-3 expressions in peripheral blood T cells. Gal-9 was localized in the regenerative areas of liver tissues in patients with acute-on-chronic liver failure, co-localizing with Kupffer cells. Kaplan-Meier survival curves showed that patients with Gal-9 levels < 9.6 ng/ml had a worse prognosis, with the area under the receiver operating characteristic curve (AUC-ROC) being similar to that of the Model for End-Stage Liver Disease score. The combined ROC curve of the two had better predictive performance, with an AUC of 0.945. High Gal-9 levels in liver regenerative areas can serve as a prognostic marker, indicating a better prognosis for patients with hepatitis B virus-acute-on-chronic liver failure.
Identifiants
pubmed: 39333198
doi: 10.1038/s41598-024-73397-6
pii: 10.1038/s41598-024-73397-6
doi:
Substances chimiques
Galectins
0
LGALS9 protein, human
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22303Subventions
Organisme : National Key Research and Development Program of China,China
ID : 2021YFC2301801
Informations de copyright
© 2024. The Author(s).
Références
Sarin, S. K. & Choudhury, A. Acute-on-chronic liver failure. Curr. Gastroenterol. Rep. 18, 61 (2016).
doi: 10.1007/s11894-016-0535-8
pubmed: 27747458
Bi, S., Earl, L. A., Jacobs, L. & Baum, L. G. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J. Biol. Chem. 283, 12248–12258 (2008).
doi: 10.1074/jbc.M800523200
pubmed: 18258591
pmcid: 2431002
An, Y. et al. Role of galectins in the liver diseases: A systematic review and meta-analysis. Front. Med. (Lausanne) 8, 744518 (2021).
doi: 10.3389/fmed.2021.744518
pubmed: 34778306
Moar, P. & Tandon, R. Galectin-9 as a biomarker of disease severity. Cell. Immunol. 361, 104287 (2021).
doi: 10.1016/j.cellimm.2021.104287
pubmed: 33494007
Golden-Mason, L. & Rosen, H. R. Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation. Hepatology 66, 271–279 (2017).
doi: 10.1002/hep.29106
pubmed: 28195343
Zhao, L., Yu, G., Han, Q., Cui, C. & Zhang, B. TIM-3: An emerging target in the liver diseases. Scand. J. Immunol. 91, e12825 (2020).
doi: 10.1111/sji.12825
pubmed: 31486085
Chou, F. C., Shieh, S. J. & Sytwu, H. K. Attenuation of Th1 response through galectin-9 and T-cell ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur. J. Immunol. 39, 2403–2411 (2009).
doi: 10.1002/eji.200839177
pubmed: 19670381
Rosen, H. R. et al. Association between plasma level of galectin-9 and survival of patients with drug-induced acute liver failure. Clin. Gastroenterol. Hepatol. 14, 606–612e3 (2016).
doi: 10.1016/j.cgh.2015.09.040
pubmed: 26499927
Sarin, S. K. et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update. Hepatol. Int. 13, 353–390 (2019).
doi: 10.1007/s12072-019-09946-3
pubmed: 31172417
Lv, Y., Ma, X., Ma, Y., Du, Y. & Feng, J. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis. 10, 2366–2382 (2023).
doi: 10.1016/j.gendis.2022.05.020
pubmed: 37554219
Fujita, K. et al. Correlation between serum galectin-9 levels and liver fibrosis. J. Gastroenterol. Hepatol. 33, 492–499 (2018).
doi: 10.1111/jgh.13851
pubmed: 28618039
Thijssen, V. L., Hulsmans, S. & Griffioen, A. W. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 172, 545–553 (2008).
doi: 10.2353/ajpath.2008.070938
pubmed: 18202194
pmcid: 2312370
Mengshol, J. A. et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLOS ONE. 5, e9504 (2010).
doi: 10.1371/journal.pone.0009504
pubmed: 20209097
pmcid: 2831996
Cardoso, F. S. et al. Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. Liver Int. 39, 1271–1280 (2019).
doi: 10.1111/liv.14083
pubmed: 30825255